유럽의 단백질체학 시장 개요 :
유럽의 단백질체학 시장 규모는 2024년 69억 1,000만 달러에서 2035년에는 CAGR 12.25%를 나타내 243억 6,000만 달러에 이를 것으로 예측됩니다. 고분해능 질량분석법과 차세대 시퀀싱 기술의 진보로 유럽에서의 단백질체학의 이용이 확대되어 보다 깊고 정밀한 단백질 분석이 가능해지고 있습니다. 새로운 바이오마커의 발견과 질병 프로파일링 기술의 향상을 목표로 하는 노력이 추진되고 있는 가운데, 이 지역에서의 맞춤형 의료에 대한 주목 증가가 수요를 더욱 증가시키고 있습니다. EU에 의한 강력한 연구자금 지원, 관민연계, 병원, 생명공학기업, 학술기관 간의 전략적 제휴로 새로운 단백질체학 응용 기술의 개발이 급속히 진행되고 있습니다. 유럽의 인구 고령화와 만성 질환 증가에 따라 진단 기술의 향상과 조기 발견 기술의 필요성이 점점 높아지고 있습니다. 이러한 요인들이 종합적으로 작용하고, 단백질체학은 임상 혁신의 기초 요소로서, 또한 이 지역에서 생명 과학 연구 생태계의 주요 추진력으로 확립되고 있습니다.
| 주요 시장 통계 | |
|---|---|
| 예측 기간 | 2025-2035년 |
| 평가(2025년) | 76억 7,000만 달러 |
| 예측(2035년) | 243억 6,000만 달러 |
| CAGR | 12.25% |
시장 분류 :
세분화 1 : 제공 구분별
세분화 2 : 용도별
세분화 3 : 지역별
유럽의 단백질체학 시장 동향·시장 성장 촉진요인 및 과제 :
동향 :
성장 촉진요인 :
과제 :
본 보고서에서는 유럽의 단백질체학 시장을 조사했으며 주요 동향, 시장 영향요인 분석, 법규제 환경, 기술·특허 분석, 시장 규모 추이와 예측, 각종 구분·지역/주요 국가별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등을 정리했습니다.
범위 및 정의
This report can be delivered in 2 working days.
Introduction to Europe Proteomics Market
The Europe proteomics market is projected to reach $24.36 billion by 2035 from $6.91 billion in 2024, growing at a CAGR of 12.25% during the forecast period 2025-2035. Advances in high-resolution mass spectrometry and next-generation sequencing technologies are increasing proteomics usage in Europe, allowing for deeper and more precise protein analysis. Demand is being further increased by the region's increasing emphasis on personalized healthcare, which is being fueled by initiatives to find new biomarkers and improve disease-profiling skills. The development of new proteomic applications is developing quickly thanks to strong EU-backed research funding, public-private partnerships, and strategic alliances between hospitals, biotech companies, and academic institutions. Improved diagnostics and early-detection technologies are becoming more and more necessary as Europe's population ages and the prevalence of chronic illnesses rises. When taken as a whole, these factors are establishing proteomics as a fundamental component of clinical innovation and a major force behind the ecosystem of life-science research in the area.
| KEY MARKET STATISTICS | |
|---|---|
| Forecast Period | 2025 - 2035 |
| 2025 Evaluation | $7.67 Billion |
| 2035 Forecast | $24.36 Billion |
| CAGR | 12.25% |
Market Introduction
Advances in high-resolution mass spectrometry and next-generation sequencing technologies are increasing proteomics usage in Europe, allowing for deeper and more precise protein analysis. Demand is being further increased by the region's increasing emphasis on personalized healthcare, which is being fueled by initiatives to find new biomarkers and improve disease-profiling skills. The development of new proteomic applications is developing quickly thanks to strong EU-backed research funding, public-private partnerships, and strategic alliances between hospitals, biotech companies, and academic institutions. Improved diagnostics and early-detection technologies are becoming more and more necessary as Europe's population ages and the prevalence of chronic illnesses rises. When taken as a whole, these factors are establishing proteomics as a fundamental component of clinical innovation and a major force behind the ecosystem of life-science research in the area.
Across the region, the push toward personalised healthcare is accelerating the adoption of proteomics in oncology, neurology, cardiology, and chronic disease management. The development of next-generation proteomic applications is being accelerated by national innovation awards, EU-funded research initiatives, and cross-border partnerships between hospitals, biotech firms, academic institutions, and CROs. This robust financing ecosystem promotes standardization, data interoperability, and clinical validation of proteomic procedures in addition to supporting scientific innovation.
The need for early detection techniques, predictive biomarkers, and more focused treatment approaches is growing as Europe's population ages and the prevalence of chronic diseases rises. Proteomics is therefore becoming recognized as a key facilitator of better patient outcomes and healthcare effectiveness. Europe is well-positioned to spearhead the next generation of clinical and technological developments in proteomics thanks to its strong infrastructure, quality-focused regulations, and developed research environment.
Market Segmentation:
Segmentation 1: By Offering
Segmentation 2: By Application
Segmentation 3: By Region
Europe Proteomics Market Trends, Drivers and Challenges
Trends
Drivers
Challenges
How can this report add value to an organization?
Product/Innovation: This report enables organizations to identify high-value opportunities in the Europe proteomics market. It guides R&D investment strategies, technology adoption, and pipeline optimization, helping companies prioritize initiatives that accelerate biomarker discovery, disease diagnostics, and therapeutic development. By highlighting emerging technologies, strategic collaborations, and platform scalability, this report helps organizations strengthen their competitive positioning and capitalize on the rapid expansion of proteomics across research, clinical, and pharmaceutical applications.
Growth/Marketing: The report delivers in-depth insights into regional adoption trends, emerging markets, and partnership opportunities, supporting strategic market entry and commercialization planning. It enables companies to identify growth potential across offering, technology, application, and end-user segments. By understanding regional R&D investments, regulatory frameworks, and technology adoption rates, organizations can refine marketing, licensing, and collaboration strategies, maximize visibility, and increase return on investment in a competitive global landscape.
Competitive: This report provides comprehensive company profiling, competitive benchmarking, highlighting strategic collaborations, funding activities, mergers, acquisitions, and technology adoption trends. Stakeholders gain a clear understanding of competitor focus areas, R&D priorities, and market positioning. This intelligence allows organizations to identify gaps, anticipate market shifts, and formulate strategies to differentiate themselves, optimize market entry, and maintain leadership in the proteomics ecosystem.
Scope and Definition